Table 2.
Number of hospital admissions following enrolment for patients assessed for medication discontinuity at follow-up
| Medication group (no patients enrolled) |
Antithrombotics (B01) (n=13 684) |
Lipid-lowering (C10) (n=14 427) |
Thyroid meds (H03) (n=3484) |
Respiratory inhalers (R03) (n=5227) |
| No patients at end of follow-up period | ||||
| 0 | 6152 (69.44%) | 6944 (72.59%) | 1641 (73.69%) | 2110 (66.41%) |
| 1 | 2011 (22.70%) | 1958 (20.45%) | 457 (20.52%) | 761 (23.95%) |
| 2 | 448 (5.06%) | 419 (4.38%) | 90 (4.04%) | 200 (6.30%) |
| 3 | 140 (1.58%) | 139 (1.45%) | 26 (1.17%) | 60 (1.89%) |
| 4 | 25 (0.28%) | 50 (5.23%) | 5 (0.23%) | 27 (0.85%) |
| 5 | 8 (0.09%) | 24 (0.25%) | 6 (0.27%) | 5 (0.16%) |
| 6 | 7 (0.08%) | 8 (0.09%) | 1 (0.04%) | 5 (0.16%) |
| >6 | 23 (0.26%) | 24 (0.25%) | 1 (0.04%) | 14 (0.44%) |